This paid-for advertorial by Promega appeared in DDW Volume 27 – Issue 3, Summer 2026. The shift from 2D monolayers to 3D cell culture models like spheroids, organoids, and complex tissue constructs, is gaining momentum in the drug discovery space. And for good reason: 3D models better recapitulate in vivo biology, improving the… Read More
Merck has entered a partnership with global life science service Promega Corporation to co-develop technologies advancing drug screening and discovery. The agreement will bring together Merck’s expertise in organoids and synthetic chemistry with Promega’s assay and reporter technologies. The companies aim to develop assays… Read More
Mitochondrial dysfunction is known to play a central role in drug-induced hepatotoxicity, and thus early detection of mitochondrial toxicity is a critical component of initial drug development efforts. While immortalised cell lines are widely used for in vitro assessment of hepatotoxicity, cryopreserved primary human hepatocytes are a preferred model for drug… Read More
Mitochondrial dysfunction is known to play a central role in drug-induced hepatotoxicity, and thus early detection of mitochondrial toxicity is a critical component of initial drug development efforts. While immortalised cell lines are widely used for in vitro assessment of hepatotoxicity, cryopreserved primary human hepatocytes are a preferred model for drug… Read More
A tiny human heart model could potentially transform cardiovascular research and enable animal-free drug testing. A team of researchers, led by the Hebrew University of Jerusalem (HU), has developed a self-paced, multi-chambered human heart model, approximately half the size of a rice grain. “Integrating… Read More
This paid-for advertorial by CN Bio appeared in DDW Volume 24 – Issue 2, Spring 2023 Despite advancements, the drug development process remains inefficient. Even with rigorous optimisation and validation, we face a 90% failure rate by the clinical phase1. Existing in vivo and in vitro models aren’t up to… Read More
Oksana Sirenko looks at the advantages and limitations of using organoids from human cell sources in drug development and drug screening. The genome is the blueprint for life, consisting of genes made up of thousands of pairs of DNA bases. Altering one base pair can drastically… Read More
Magnitude Biosciences has closed a fourth round of investment to accelerate the scaling of its business providing C. elegans research services. A total investment of £500,000 will be made by longstanding investors the North East (ERDF) Innovation Fund Limited Partnership, supported by the European Regional Development Fund… Read More
DDW Editor Reece Armstrong explores some of the trends that will be featured in sessions throughout ELRIG Drug Discovery 2022 and the news behind them. Taking place at the ExCel in London from 4-5 October, ELRIG Drug Discovery 2022 is set to provide visitors with access to the… Read More
ELRIG CEO Sanj Kumar tells readers how they can access the most exciting research and find the latest technologies to propel their projects forward at this year’s Drug Discovery 2022 At ELRIG, our purpose is to support researchers in the life sciences and drug discovery communities to learn, share,… Read More
Life sciences company Carterra has joined data cloud company TetraScience’s network of partners to help generate insights into the potential of antibodies as drug candidates. The Tetra Partner Network (TPN) is an ecosystem of partners which connects R&D data for pharmaceutical and biopharmaceutical customers. Carterra… Read More
This paid-for advertorial by Eurofins Discovery appeared in Volume 23 – Issue 3, Summer 2022. In the following article, Luke Oostdyk, Lakshmi Anantharaman and Nicole Servant from Eurofins Discovery discuss how G-Protein Coupled Receptor screening and profiling can advance drug discovery programs. The sheer number of understudied and orphan receptors in… Read More
Biopharmaceutical company Orbit Discovery has been awarded almost £500,000 in a grant to help it expand its microfluidics screening capabilities. The £472,000 Smart grant was awarded by Innovate UK and will facilitate the implementation of droplet-based microfluidics for cell-based functional screening and expand the capabilities and throughput… Read More
NanoTemper Technologies has launched a number of updates to its portfolio of instruments to help researchers working in drug discovery and adeno-associated virus (AAV) therapies. NanoTemper Technologies has launched its Spectral Shift technology to remove the roadblocks experienced by scientists dealing with really complex molecular interactions often… Read More
CAR T cell technology provides the foundation for established immunotherapies against certain types of blood cancer and holds great promise for the fight against many solid tumours too. One major drawback of conventional CAR T cell technology, which relies on a single target antigen, is the lack of tumour-associated antigens (TAAs) that… Read More
Multiplex assays allow researchers to measure multiple biomarkers simultaneously, offering the advantage of harvesting more insightful data to inform better decision-making, accelerate research, and increase the probability of discovery. Enabling biomarker discovery and screening with FirePlex Multiplexed Assays features the expertise of Dr Paul Wylie. In this webinar with… Read More
